Data for the incidence and prevalence of gastritis are not available. Dyspeptic symptoms affect up to 25% of the population of the United States; nonulcer dyspepsia (including gastritis) contributes to the diagnosis in about 50% of patients referred for upper endoscopy.[17]El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther. 2004 Mar 15;19(6):643-54.
http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2004.01897.x/full
http://www.ncbi.nlm.nih.gov/pubmed/15023166?tool=bestpractice.com
Dyspeptic symptoms are reported in 10% to 20% of patients taking nonsteroidal anti-inflammatory drugs (NSAIDs), although the prevalence may range from 5% to 50%.[18]Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 1987 Nov;82(11):1153-8.
http://www.ncbi.nlm.nih.gov/pubmed/3499815?tool=bestpractice.com
[19]Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med. 1996 Jul 22;156(14):1530-6.
http://www.ncbi.nlm.nih.gov/pubmed/8687261?tool=bestpractice.com
North European or Scandinavian ancestry is a recognized risk factor for autoimmune gastritis.[10]Kekki M, Siurala M, Varis K, et al. Classification principles and genetics of chronic gastritis. Scand J Gastroenterol Suppl. 1987;141:1-28.
http://www.ncbi.nlm.nih.gov/pubmed/3481655?tool=bestpractice.com
The prevalence of Helicobacter pylori infection is higher in developing countries and is impacted by a multitude of factors, including geography, age, strain virulence, environmental factors, and socioeconomic status.[20]World Gastroenterology Organisation. WGO Global Guidelines. Helicobacter pylori. May 2021 [internet publication].
https://www.worldgastroenterology.org/guidelines/helicobacter-pylori/helicobacter-pylori-english